Skip To Main Content
Imke H Bartelink on Muck Rack

Imke H Bartelink

As seen in: Nature, Wiley Online Library, British Pharmacological Society, MDPI, Journal of Nuclear Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Imke H

Contact Imke H, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pediatric pharmacokinetics and pharmacodynamics of guanabenz for the treatment of vanishing white matter Original

|
By Renate J. Verbeek, Marije M.C. Voermans, Pierre M. Bet, Ron A. A. Mathôt, Dennis van der Laan, Imke H Bartelink, Linda G. Franken, Bart van Lieshout, Joshua Eugenio, Elske van den Berg, Truus E. M. Abbink, Marjo S. van der Knaap
| Nature Verified
Abstract Vanishing White Matter (VWM) is a leukodystrophy with cystic cerebral white matter degeneration, resulting in neurological decline and premature death. There is currently no treatment. Guanabenz, a central α2-adrenergic receptor agonist, ameliorates the disease in VWM mouse models.
Open in Who Shared View Duplicates (2) Issue with article?

Methotrexate toxicity and glucarpidase: A call for dose optimization

|
By Arjen Koppen, Maaike A. Sikma, Frederike K Engels, Imke H Bartelink
| British Pharmacological Society
1 HIGH-DOSE METHOTREXATE THERAPY, DELAYED RENAL CLEARANCE AND GLUCARPIDASE High-dose methotrexate (HDMTX) is a folic acid antagonist that is used to treat acute lymphoblastic leukaemia, lymphoma and osteosarcoma in adult and paediatric patients. HDMTX cytotoxicity is concentration and time-dependent.
Open in Who Shared Issue with article?

Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET

|
By André N. Vis, Imke H Bartelink, Marina Hodolic, Josephina C.C. Koppes
| Journal of Nuclear Medicine Verified
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Open in Who Shared View Duplicates (8) Issue with article?
See all 6 articles